XML 144 R30.htm IDEA: XBRL DOCUMENT

Subsequent Events Subsequent Events	6 Months Ended
Subsequent Events Subsequent Events	Jun. 30, 2013
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On July 1, 2013, we entered into a Platform Agreement with Adimab LLC (Adimab). Pursuant to the agreement, Adimab granted us a non-exclusive license to its proprietary antibody discovery platform. We will record this arrangement as an R&D asset as we plan to use the technology in various R&D activities.